IMPORTANT SAFETY INFORMATION
OMIDRIA
®
must be added to irrigation solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure of phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic
acid derivatives, and other non-steroidal anti-infl ammatories (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at 2-24% are eye irritation, posterior capsule opacifi cation, increased
intraocular pressure, and anterior chamber infl ammation.
Use of OMIDRIA in children has not been established.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.
INDICATIONS AND USAGE
OMIDRIA is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is
indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation.
The fi rst and only FDA-approved product that combines
miosis prevention and post-op ocular pain reduction in one
1
Introducing
OMIDRIA
®
(phenylephrine and ketorolac injection) 1% / 0.3%
IS COVERED FOR MORE CATARACT
SURGERY PATIENTS THAN YOU THINK
